126520-01-2Relevant articles and documents
Pyrazolotriazines as inhibitors of nucleases
-
Paragraph 0122; 0123; 0124; 0125; 0126; 0127; 0158-0163, (2016/01/12)
The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3 and R4 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
Development of two synthetic routes to CE-178,253, a CB1 antagonist for the treatment of obesity
Brandt, Thomas A.,Caron, Stéphane,Damon, David B.,DiBrino, Joseph,Ghosh, Arun,Griffith, David A.,Kedia, Sandeep,Ragan, John A.,Rose, Peter R.,Vanderplas, Brian C.,Wei, Lulin
experimental part, p. 3292 - 3304 (2009/08/08)
CE-178,253 benzenesulfonate (1) is a CB1 antagonist discovered by Pfizer medicinal chemists. Two syntheses of this compound are described. The first, based on the discovery synthesis, involves assembly of an aryl-substituted pyrazolotriazine core onto which the second aryl moiety is installed by a Suzuki coupling; this route has been scaled to provide up to 6 kg of API. A second, more convergent route is also described, which installs the pyrazolotriazine containing both aryl substituents by condensation of a bromoketone with a substituted thiosemicarbazide. This route has been demonstrated on laboratory scale and is viewed as the preferred bond-forming sequence.
PYRAZOLO`1,5-A!`1,3,5! TRIAZIN -4-ONE DERIVATIVES AS CB1 RECEPTOR ANTAGONISTS
-
Page/Page column 43, (2010/02/12)
Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.
